Literature DB >> 12716702

Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.

J McVernon1, P D R Johnson, A J Pollard, M P E Slack, E R Moxon.   

Abstract

AIMS: To compare the convalescent antibody response to invasive Haemophilus influenzae type b (Hib) disease between conjugate vaccine immunised and unimmunised children, to look for evidence of priming for immunologic memory.
METHODS: Unmatched case-control study in the UK and Eire 1992-2001 and Victoria, Australia 1988-1990. A total of 93 children were identified as having invasive Hib disease following three doses of conjugate vaccine in infancy through post licensure surveillance throughout the UK and Eire; 92 unvaccinated children admitted to an Australian paediatric hospital with invasive Hib disease were used as historical controls. Convalescent serum was taken for measurement of Hib antibody concentration, and clinical information relating to potential disease risk factors was collected. The geometric mean concentrations of convalescent Hib antibodies were compared between immunised and unimmunised children, using raw and adjusted data.
RESULTS: Hib conjugate vaccine immunised children had higher serum Hib antibody responses to disease (geometric mean concentration (GMC) 10.81 microg/ml (95% CI 6.62 to 17.66) than unimmunised children (1.06 microg/ml (0.61 to 1.84)) (p < 0.0001). However, following adjustment for the significant confounding influences of age at presentation and timing of serum collection, a difference persisted only in children presenting with meningitis (vaccinated GMC 3.78 microg/ml (2.78 to 5.15); unvaccinated GMC 1.48 microg/ml (0.90 to 2.21); p = 0.003).
CONCLUSIONS: Higher antibody responses to invasive Hib disease in vaccinated children with meningitis reflect priming for immunologic memory by the vaccine. Although a majority of children in the UK are protected from Hib disease by immunisation, the relative roles of immunologic memory and other immune mechanisms in conferring protection remain unclear.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716702      PMCID: PMC1719572          DOI: 10.1136/adc.88.5.379

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  27 in total

1.  Differing serologic responses to an haemophilus influenzae type b polysaccharide-neisseria meningitidis outer membrane protein conjugate (PRP-OMPC) vaccine in australian aboriginal and caucasian infants - implications for disease epidemiology.

Authors:  S Guthridge; P McIntyre; D Isaacs; M Hanlon; M Patel
Journal:  Vaccine       Date:  2000-05-22       Impact factor: 3.641

Review 2.  Science, medicine, and the future: susceptibility to infection.

Authors:  D Kwiatkowski
Journal:  BMJ       Date:  2000-10-28

3.  Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.

Authors:  R Borrow; J Southern; N Andrews; N Peake; R Rahim; M Acuna; S Martin; E Miller; E Kaczmarski
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

4.  Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b.

Authors:  R Schneerson; L P Rodrigues; J C Parke; J B Robbins
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

5.  Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines.

Authors:  M H Slack; D Schapira; R J Thwaites; M Burrage; J Southern; N Andrews; R Borrow; D Goldblatt; E Miller
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

6.  Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies.

Authors:  T Nieminen; H Käyhty; O Leroy; J Eskola
Journal:  Pediatr Infect Dis J       Date:  1999-09       Impact factor: 2.129

7.  Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants.

Authors:  M A Breukels; L Spanjaard; L A Sanders; G T Rijkers
Journal:  Clin Infect Dis       Date:  2001-05-16       Impact factor: 9.079

8.  Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood.

Authors:  P T Heath; R Booy; H Griffiths; E Clutterbuck; H J Azzopardi; M P Slack; J Fogarty; A C Moloney; E R Moxon
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

9.  Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.

Authors:  P T Heath; R Booy; H J Azzopardi; M P Slack; J Bowen-Morris; H Griffiths; M E Ramsay; J J Deeks; E R Moxon
Journal:  JAMA       Date:  2000-11-08       Impact factor: 56.272

10.  Hib vaccination in infants born prematurely.

Authors:  P T Heath; R Booy; J McVernon; J Bowen-Morris; H Griffiths; M P E Slack; A C Moloney; M E Ramsay; E R Moxon
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

View more
  16 in total

1.  Haemophilus influenzae type b epiglottitis. Occasional cases will present.

Authors:  Carline Lee; Andrew Coatsworth
Journal:  BMJ       Date:  2003-02-01

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

3.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

4.  Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

Authors:  Mark J Abzug; Lin Ye Song; Myron J Levin; Sharon A Nachman; William Borkowsky; Stephen I Pelton
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641

5.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

6.  Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.

Authors:  Dominic F Kelly; E Richard Moxon; Ly-Mee Yu; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

Review 7.  Haemophilus influenzae type b conjugate vaccines.

Authors:  Dominic F Kelly; E Richard Moxon; Andrew J Pollard
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

Review 8.  Bacterial meningitis: the impact of vaccination.

Authors:  Nick Makwana; F Andrew I Riordan
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review.

Authors:  Mary Paulina Elizabeth Slack
Journal:  Microorganisms       Date:  2021-04-21

Review 10.  Importance of circulating antibodies in protection against meningococcal disease.

Authors:  Kim S Erlich; Blaise L Congeni
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.